plozasiran

News

Sanofi grabs Chinese rights to Arrowhead rare disease drug

Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug for rare disease familial chylomicronaemia syndrome.

News

Ionis, Arrowhead hail data with triglyceride drugs at ACC

Drugs from Ionis and Arrowhead Pharma that block apolipoprotein C-III (apoC-III) have shown their value in treating diseases associated with elevated triglyceride levels i

News

Vogenx surpasses expectations with $81M IPO

With $81.3 million raised, Vogenx is the latest in a staggering summer of biotech IPOs. But the queue past this point looks thin.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks